Okairos, A Basel, Switzerland-based clinical-stage biopharmaceutical company, completed a €16m Series B private financing round.
The investment was led by Versant Ventures, with participation from the Boehringer Ingelheim Venture Fund, BioMedPartners, LSP and Novartis Venture Funds.
Using a novel proprietary technology, Okairos follows an innovative approach to engage the cellular arm of the immune system, specifically T-cells, to fight infectious diseases including malaria, HIV, hepatitis C and universal influenza.
The funds will be used to advance the company’s portfolio of prophylactic and therapeutic vaccines through clinical proof-of-concept.
Okairos, which is also exploring therapeutic vaccines to treat cancer, has laboratories in Rome and Naples, Italy.